Effect of nitric oxide donors on survival of conidia, germination and growth of Aspergillus fumigatus in vitro
Language English Country United States Media print
Document type Journal Article
PubMed
8919928
DOI
10.1007/bf02814199
Knihovny.cz E-resources
- MeSH
- Aspergillus fumigatus drug effects growth & development metabolism MeSH
- Aspergillosis metabolism microbiology MeSH
- Sodium Nitrite metabolism pharmacology MeSH
- Hydrogen-Ion Concentration MeSH
- Humans MeSH
- Nitric Oxide metabolism pharmacology MeSH
- Spores, Fungal drug effects MeSH
- In Vitro Techniques MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Sodium Nitrite MeSH
- Nitric Oxide MeSH
The effect of nitric oxide (NO) donors on survival of conidia, germination and growth of the opportunistic pathogenic fungus Aspergillus fumigatus was investigated. Most efficient was sodium nitrite in an acidic milieu (pH 4.5). At a concentration of 5 mmol/L it killed all resting conidia in buffer within 16 h. S-Nitroso derivatives of thiols (cysteine, N-acetylcysteine and N-acetylpenicillamine) at the same concentration killed about 30-50% of spores within 24 h. The NO scavenger, oxyhemoglobin, abolished these effects. S-Nitrosoglutathione had no fungicidal effect and promoted germination. Sodium nitrite and S-nitroso-N-acetylcysteine inhibited germination of conidia in various media from concentration of 0.5 mmol/L and stopped it at concentrations of 1.4-2.9 mmol/L. In media with glucose and casein hydrolyzate or sodium nitrate as nitrogen source, growth inhibition by sodium nitrite (0.5-2 mmol/L) was only weak and mostly transient. In general, the used strain A. fumigatus seems to be less sensitive to nitric oxide donors than dimorphic pathogenic fungi. Thus, nitric oxide is probably not a major effector molecule in killing phagocytized elements of this fungus by host's immunocytes.
See more in PubMed
Environ Health Perspect. 1992 Jul;97:115-20 PubMed
Infect Immun. 1993 May;61(5):1980-9 PubMed
Infect Immun. 1991 Jul;59(7):2291-6 PubMed
Eur J Immunol. 1993 May;23(5):1034-8 PubMed
Infect Immun. 1994 Apr;62(4):1478-9 PubMed
Res Immunol. 1991 Sep;142(7):570-2; discussion 599-600 PubMed
Infect Immun. 1994 Feb;62(2):680-4 PubMed
Eur J Immunol. 1993 Jun;23(6):1385-8 PubMed
Br J Pharmacol. 1992 Nov;107(3):745-9 PubMed
Br J Pharmacol. 1992 Nov;107(3):715-21 PubMed
Infect Immun. 1994 May;62(5):1940-5 PubMed
J Immunol. 1994 Apr 1;152(7):3514-21 PubMed
Jpn J Pharmacol. 1992;58 Suppl 2:185P-191P PubMed
Curr Opin Immunol. 1991 Feb;3(1):65-70 PubMed
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8103-7 PubMed
Ann Trop Med Parasitol. 1993 Dec;87(6):637-42 PubMed
J Clin Invest. 1988 Apr;81(4):1129-36 PubMed
Immunol Ser. 1994;60:29-46 PubMed
J Med Vet Mycol. 1992;30 Suppl 1:167-77 PubMed
J Pharmacol Exp Ther. 1990 Dec;255(3):1256-64 PubMed
Recent Results Cancer Res. 1993;132:109-15 PubMed
J Clin Invest. 1990 Jan;85(1):264-73 PubMed
J Exp Med. 1994 Jul 1;180(1):365-9 PubMed
Science. 1992 Dec 18;258(5090):1898-902 PubMed
Biokhimiia. 1993 Jul;58(7):1094-103 PubMed
Infect Immun. 1994 Jul;62(7):3004-7 PubMed
Anal Biochem. 1992 Aug 1;204(2):365-71 PubMed
